AC-201 not checked
TWi Biotechnology, Inc. · AC-203
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “The investigational product is formulated as 1% topical ointment”In the company’s words, NCT06073132 on ClinicalTrials.gov
- Main trialPhase 2/3
- “The proposed Phase 2/3 trial with double-blind and open-label extension phases is an international, multicenter study designed to assess the efficacy and safety of diacerein 1% ointment in patients with generalized EBS.”In the company’s words, NCT06073132 on ClinicalTrials.gov
- Other names
- AC-203
Other drugs for Generalized Epidermolysis Bullosa Simplex
- TolaSure Topical GelBioMendics, LLC · Phase 2
- ENERGI-F703Energenesis Biomedical Co., Ltd. · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Active, not recruiting | 10 Jun 2026 | An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) | |
| Phase 2Completed | 27 Oct 2016 | A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026